Lam Chen-Fuh, Van Heerden P Vernon, Blott John, Roberts Brigit, Ilett Kenneth F
School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
J Crit Care. 2004 Mar;19(1):48-53. doi: 10.1016/j.jcrc.2004.02.009.
To examine the effects of inhaled NONOates in patients with acute respiratory distress syndrome (ARDS).
Case-series, phase I clinical trial.
A multidisciplinary intensive care unit in a tertiary teaching hospital.
Five consecutive patients with ARDS (men; age range, 47-76 years).
DETA/NO (150 micromol) was aerosolized into the lungs of patients on mechanical ventilation via the endotracheal tube over 20 minutes. Hemodynamic parameters were measured and blood samples were taken before, during, and after inhalation.
Compared to baseline values, pulmonary vascular resistance decreased until the end of the study period (180 minutes) while intrapulmonary shunting decreased significantly up to 45 min after DETA/NO aerosol administration. Inhaled DETA/NO had no effect on the systemic circulation (systemic blood pressure or cardiac output).
Inhaled DETA/NO is a selective pulmonary vasodilator in patients with ARDS. However, a larger number of patients is required to confirm the findings of this pilot study.
研究吸入亚硝基铁氰化钠（NONOates）对急性呼吸窘迫综合征（ARDS）患者的影响。
病例系列Ⅰ期临床试验。
一家三级教学医院的多学科重症监护病房。
连续5例ARDS患者（男性；年龄范围47 - 76岁）。
通过气管内导管将DETA/NO（150微摩尔）雾化至机械通气患者肺内，持续20分钟。在吸入前、吸入期间和吸入后测量血流动力学参数并采集血样。
与基线值相比，肺血管阻力在研究期结束时（180分钟）降低，而肺内分流在DETA/NO雾化给药后45分钟内显著降低。吸入DETA/NO对体循环（体循环血压或心输出量）无影响。
吸入DETA/NO是ARDS患者的一种选择性肺血管扩张剂。然而，需要更多患者来证实这项初步研究的结果。
